SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD).

加利福尼亚州南旧金山，2023年9月7日（GLOBE NEWSWIRE）-临床阶段生物技术公司Alector，Inc。（纳斯达克股票代码：ALEC）开拓免疫神经病学，今天宣布已完成登记。2，AL002的2期临床试验。CHAKE-2正在评估AL002在减缓早期阿尔茨海默病（AD）患者疾病进展中的安全性和有效性。

Data from the trial are expected in the fourth quarter of 2024. AL002 is a novel investigational humanized monoclonal antibody (mAb) that binds to triggering receptor expressed on myeloid cells 2 (TREM2). AL002 is the most advanced TREM2 activating product candidate in clinical trials and is being developed in collaboration with AbbVie.

审判数据预计在2024年第四季度。AL002是一种新型研究性人源化单克隆抗体（mAb），可与髓样细胞2（TREM2）上表达的触发受体结合。AL002是临床试验中最先进的TREM2激活产品候选者，正在与AbbVie合作开发。

“The successful completion of enrollment in the INVOKE-2 Phase 2 trial marks a significant milestone in the ongoing development of AL002, bringing us one step closer to potentially introducing this prospective new class of therapeutics to individuals impacted by Alzheimer's disease,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.

阿农·罗森塔尔（Arnon Rosenthal）博士说：“APVODE-2第二阶段试验的成功完成标志着AL002正在进行的发展中的一个重要里程碑，使我们更接近可能将这种前瞻性的新型治疗药物引入受阿尔茨海默病影响的个体。”Alector首席执行官博士。

“We are also encouraged to see that nearly all eligible participants are rolling over into the long-term extension of the INVOKE-2 trial, which will enable us to better understand the long-term effects of this potential therapeutic. Notably, results from a Phase 1 clinical trial of AL002 in healthy volunteers demonstrated both dose dependent target engagement and activation of microglia.

“我们也被鼓励看到，几乎所有符合条件的参与者都参与了CHARGE-2试验的长期延期，这将使我们能够更好地了解这种潜在治疗方法的长期效果。值得注意的是，健康志愿者中AL002的1期临床试验证明了剂量依赖性靶标参与和小胶质细胞的活化。

We look forward to an INVOKE-2 data readout in the fourth quarter of 2024, which will inform a potential pivotal Phase 3 clinical development program for AL002 that enables registration.” INVOKE-2 is a randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 clinical trial being conducted at m.

我们期待在2024年第四季度发布VOCUDE-2数据读数，这将为AL002的潜在关键3期临床开发计划提供信息，从而实现注册。”CALQUE-2是一项随机，双盲，安慰剂对照，剂量范围的多中心2期临床试验，正在m。